



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
DIVISION OF HEALTH CARE FINANCING AND POLICY
Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, April 17, 2025

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),
Drug Use Review Board

Agenda Item	Record	Notes																								
1) Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Vice-Chair Neto Adeolokun called the meeting to order at 1:00 p.m. on April 17, 2025.</p> <p>Vice-Chair Adeolokun took the roll.</p> <table border="0"> <thead> <tr> <th></th><th>Present</th><th>Absent</th></tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td align="center"><input type="checkbox"/></td><td align="center"><input checked="" type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td align="center"><input checked="" type="checkbox"/></td><td align="center"><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td align="center"><input type="checkbox"/></td><td align="center"><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td align="center"><input type="checkbox"/></td><td align="center"><input checked="" type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td align="center"><input checked="" type="checkbox"/></td><td align="center"><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td align="center"><input checked="" type="checkbox"/></td><td align="center"><input type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td align="center"><input checked="" type="checkbox"/></td><td align="center"><input type="checkbox"/></td></tr> </tbody> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff present were as follows:</p> <ul style="list-style-type: none"> • Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director • Brown, Antonio, Chief of Pharmacy & DME • Palomino, Bonnie, Pharmacy Services Manager • Cabrera, Donna, Program Officer I • Driscoll, Lauren, Deputy Attorney General (DAG) <p>Prime Therapeutics Staff Present were as follows:</p> <ul style="list-style-type: none"> • Mishra, Raj, Pharm.D., Clinical Account Manager • Martinez, Chris, Sr. Business Analyst • Deoliveira, Brittany, Pharm.D., Clinical Account Manager • Czechowski, Jessica, Pharm.D., Director, Clinical Account Services • Facchini, Victoria, Pharm.D., Director, Specialty Clinical Solutions
	Present	Absent																								
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								

		<p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none">• Bitton, Ryan, Pharm.D., Health Plan of Nevada• Beranek, Tom, Pharm.D., Silver Summit Health Plan• Tran, Jimmy, Pharm.D., Molina Healthcare• Ahmed, Shadi, Pharm.D., Anthem <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>												
2) General Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>													
3) Administrative														
a) For Possible Action: Review and Approve Meeting Minutes from January 16, 2025.	<p>Board Member Dave England moved to approve the minutes as presented, and Board Member Jim Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> • Crystal Castaneda, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
b) Status Update by DHCFP	<p>Medicaid Pharmacy Director Dr. Keiko Duncan provided an announcement.</p> <p>We are, as I think most people know, a few months into the legislative session.</p> <p>So it's been quite an exciting session. For anybody following, there have been quite a few bills specific to the medical benefit as well as the pharmacy benefit.</p> <p>A couple things I just wanted to put in front of you all, that you probably already know, the Nevada Governor did release his plan at the start of January regarding the Nevada Health Authority.</p> <p>With the Nevada Health Authority, should that be approved through sessions, Nevada Medicaid would move under that authority. It does not change anything we are doing here today with the Drug Utilization Review Board but there would be a new structure should that pass.</p> <p>The other point that I wanted to raise was brought forth in our Medicaid budget a couple weeks ago. It was presented that we would move to a single preferred drug list and, if that is approved through legislative session, we would be moving to that within the next biennium. We will have some more announcements at our next meeting as we see fit.</p> <p>As we always announce, we are still recruiting members for this DUR Board as well as the Silver State Script Board. If you know any physicians, physician assistants, or pharmacists, please reach out. It's just as simple as sending over a CV to our e-mail: Rxinfo@dhcfp.nv.gov. You can also go online on our Nevada Medicaid website.</p>	

4) Clinical Presentations		
a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).		
i) Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii) Presentation of utilization and clinical information.	Dr. Raj Mishra provided the clinical background and indications for Alytrek. Dr. Mishra reviewed the proposed criteria presented in the binder for Alytrek.	

	<ul style="list-style-type: none">• Dr. Ryan Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Tom Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Shadi Ahmed with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	Vice- Chairperson Adeolokun asked for comments from the Board Members. No comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics and Board Member Brain Le seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Filsuvez (birch triterpenes) .																																		

i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Turner Leland.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Filsuvez.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Filsuvez.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
iii) Discussion by Board and review of utilization data.	<p>Vice- Chairperson Adeolokun asked for comments from the Board Members.</p> <p>No comment was made.</p>	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<div> <div> Yes No Abst. </div> <div> <ul style="list-style-type: none"> Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice-Chair Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Jim Tran, Pharm.D. </div> <div> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> </div> </div>	
c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Juxtapid (lomitapide) .		
i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Juxtapid.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Juxtapid.</p> <ul style="list-style-type: none"> Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	

iii) Discussion by Board and review of utilization data.	Vice-Chair Adeolokun asked for comments from the Board Members. No comment was made.																																					
iv) Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Prime Therapeutics, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>•</td><td></td><td></td><td></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	•				
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
•																																						
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Primary Biliary Cholangitis (PBC) agents.																																						
i) Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.																																					

ii) Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Ocaliva® (obeticholic acid), Iqirvo® (elafibranor), Livdelzi®(seladelpar).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Primary Biliary Cholangitis.</p> <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	<p>Vice Chair Adeolokun asked for comments from the Board Members.</p> <p>No comment was made.</p>																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

<p>e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Phosphodiesterase-4 Inhibitors or combination.</p>		
<p>i) Public comment on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Ohtuvayre.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Phosphodiesterase-4 Inhibitors or combination</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Vice-Chair Adeolokun, asked for comments from the Board Members.</p> <p>No comment was made.</p>	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p>	

	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
f) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Immunomodulator Drugs.																																		
i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Amy Hale.</p> <p>Public comment was provided by Alexandra Kaiser.</p> <p>Public comment was provided by Melinda Turkington.</p>																																	

<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Rinvoq and Cibinqo.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Immunomodulator Drugs.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Vice-Chair Adeolokun asked for comments from the Board Members.</p> <p>No comment was made.</p>	

iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Le seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Tryngolza (olezarsen) .																																		
i) Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	

ii) Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Tryngolza.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Tryngolza.</p> <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	<p>Vice-Chair Adeolokun, asked for comments from the Board Members.</p> <p>No comment was made.</p>																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

<p>h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Yorvipath (palopegteriparatide).</p>		
<p>i) Public comment on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Christie Bama.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Yorvipath.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Yorvipath.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	

iii) Discussion by Board and review of utilization data.	Vice-Chair Adeolokun, asked for comments from the Board Members. No comment was made.																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Zepbound (tirzepatide) .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Zepbound.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Zepbound.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
iii) Discussion by Board and review of utilization data.	<p>Vice - Chair Adeolokun asked for comments from the Board Members.</p> <p>No comment was made.</p>	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<div> <div></div> <div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> </div> <ul style="list-style-type: none"> • Jennifer Wheeler, Pharm.D., Chair <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Netochi Adeolokun, Pharm.D., Vice-Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Crystal Castaneda, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
j. Opioid Utilization Reports: <ul style="list-style-type: none"> i) Opioid Trends ii) Top Members iii) Top Prescribers iv) Top Pharmacies 	<ul style="list-style-type: none"> • Dr. Mishra presented opioid utilization reports. • Dr. Bitton presented opioid utilization reports. • Dr. Beranek presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. • Dr. Ahmed presented opioid utilization reports. <p>Vice-Chair Adeolokun asked for comments from Board Members regarding Opioid Reports. The Board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>	
k. Standard DUR Reports: <ul style="list-style-type: none"> i) Top 10 Therapeutic Classes ii) ProDUR Paid Claims Savings Report iii) RetroDUR DUR Initiatives 	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports. • Dr. Beranek presented Standard DUR Reports. • Dr. Tran presented Standard DUR Reports. • Dr. Ahmed presented Standard DUR Reports. 	

<p>m. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Physician Administered Drugs.</p>	<ul style="list-style-type: none"> • Aranesp (darbepoetin alfa) • bevacizumab • Bavencio (avelumab) • Darzalex (daratumumab) • Imfinzi (durvalumab) • Jemperli (dostarlimab-gxly) • Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • Opdivo (nivolumab) • paclitaxel albumin-bound • pemetrexed • rituximab IV • rituximab SQ • Susvimo (ranibizumab) • Tecentriq (atezolizumab) • trastuzumab IV • Yervoy (ipilimumab) 	
--	--	--

<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comments were provided.</p>	
<p>ii) Presentation of utilization and clinical information</p>	<p>Dr. Victoria Facchini reviewed the proposed criteria updates presented in the binder:</p> <ul style="list-style-type: none"> • Aranesp (darbepoetin alfa) • bevacizumab • Bavencio (avelumab) • Darzalex (daratumumab) • Imfinzi (durvalumab) • Jemperli (dostarlimab-gxly) • Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • Opdivo (nivolumab) • paclitaxel albumin-bound • pemetrexed • rituximab IV • rituximab SQ • Susvimo (ranibizumab) • Tecentriq (atezolizumab) • trastuzumab IV • Yervoy (ipilimumab) 	

	<ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	Vice-Chair Adeolokun, asked for comments from the Board Members. No Comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Prime Therapeutics and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
5) Closing Discussion																																		
a. Public Comment	Telephonic and web comments were called for, and the phone lines were opened. No public comment was provided.																																	

b. For Possible Action: Date and location of the next meeting.	<p>Vice-Chair Adeolokun stated the next meeting is scheduled for July 31, 2025.</p> <p>Location: Hilton Garden Inn Reno</p> <p>Meeting adjourned at 3:02 pm</p>	
--	---	--

Attachment A – Members of the Public in Attendance

Aaron Girvin	Jennifer Golwyn	Nick Trombold
Stefanie Abraham	JJ Roth	Turkington Melinda
Ryan A Roa	Joleen Walker	TURNER Leland
Andi Stratton	Marilyn Juarez	Tyler Lincoln
Ann Marie O'Toole	Alexandra Kaiser	William Lam
Brent Fushimi	Kaysen Bala	Kenneth Garcia
Olivia Capperella	Lisa Glick	Lee Stout
Fushimi Brent	Lisa Pulver	Chi Kohlhoff
GPAP (Ginger Papesh)	Rianna White	
Amy Hale	Jason Douglas	

Attachment B – Submitted Written Comment

None

